UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 146.67% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Oppenheimer restated an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.70.

UroGen Pharma Price Performance

Shares of URGN stock traded down $0.11 during mid-day trading on Wednesday, hitting $10.14. 114,478 shares of the stock traded hands, compared to its average volume of 354,846. UroGen Pharma has a twelve month low of $9.78 and a twelve month high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The company’s 50-day simple moving average is $10.92 and its 200-day simple moving average is $12.41. The firm has a market cap of $237.67 million, a price-to-earnings ratio of -3.21 and a beta of 1.08.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Several large investors have recently bought and sold shares of the stock. Rosalind Advisors Inc. bought a new stake in shares of UroGen Pharma during the fourth quarter valued at approximately $9,266,000. Vestal Point Capital LP acquired a new position in shares of UroGen Pharma in the 3rd quarter worth approximately $5,080,000. Stonepine Capital Management LLC bought a new position in UroGen Pharma in the 3rd quarter valued at $3,560,000. RTW Investments LP boosted its position in shares of UroGen Pharma by 6.5% in the 3rd quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after purchasing an additional 230,000 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its position in shares of UroGen Pharma by 273.6% during the 3rd quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock worth $3,453,000 after buying an additional 199,110 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.